HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Abacavir (Ziagen) Research

See also: Medication Side Effects | Drug Interactions

Show Archived (Historical) Articles

2006-2009

Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
Abacavir Efficacy and Cardiovascular Risk (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir (April 4, 2008)
To read PDF, click here
From AIDSinfo
Major Study Finds Red Flags When Using Epzicom as First-Line Therapy in People With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases
Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here
From D:A:D Steering Committee
Study Finds Heart Trouble With Ziagen and Videx (February 4, 2008)
From Project Inform
Abacavir Hypersensitivity Test Could Be Combined With Drug Resistance Test: Study (June 4, 2007)
From aidsmap.com
In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections

2003

Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.